Lakefront Biotherapeutics American Depositary Shares
LKFT
85 hedge funds and large institutions have $887M invested in Lakefront Biotherapeutics American Depositary Shares in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 18 closing their positions.
80% more call options, than puts
Call options by funds: $28.7M | Put options by funds: $16M
17% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 18
13% more capital invested
Capital invested by funds: $783M → $887M (+$104M)
2% more funds holding
Funds holding: 83 → 85 (+2)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0.77% more ownership
Funds ownership: 47.33% → 48.1% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$50.3M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$23.6M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$12.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.16M |
| 5 |
Renaissance Technologies
New York
|
+$3.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$36.5M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$18.6M |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$16.5M |
| 4 |
NM
Newtyn Management
New York
|
-$5.02M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$5.02M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
JP Morgan Chase
New York
| – | -$22.4K | -835 | Closed |
|
|
HCP
102
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$3.34K | -133 | Closed |
|
|
BIG
103
Brooklyn Investment Group
Brooklyn,
New York
| – | -$1.86K | -74 | Closed |
|
LKFT Hedge Fund Activity: Q2 2025 in Review
85 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2025, worth a combined $887M — up 13% from $783M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new LKFT positions and 18 closed out — a net gain of 3 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $50.3M. The largest seller was BVF Inc, exiting entirely with an estimated $36.5M sold.
- 85 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2025, up from 83 in Q1 2025.
- Funds reported $887M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2025, up 13% quarter-over-quarter.
- 21 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2025 and 18 closed out, a net change of +3 holders.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2025 was Madison Avenue Partners, an estimated $50.3M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2025 was BVF Inc, an estimated $36.5M sold.
Based on aggregated 13F filings for Q2 2025.